ArticleBreast cancer research and treatment2008
Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Article in Breast cancer research and treatment, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.Frontiers in immunology · 2024Review
- Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives.Cancers · 2020Review
- Three-dimensional tumor cell cultures employed in virotherapy research.Oncolytic virotherapy · 2018Review
- The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic CancerCurrent cancer drug targets · 2018Review
- Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.Molecular therapy oncolytics · 2015Article
- Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Future virology · 2013Article
- Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in mice.PloS one · 2013Article
- Oncolytic virotherapy.Nature biotechnology · 2012Review
- Fibroblast growth factor and ornithine decarboxylase 5'UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN(-/-) transgenic mice.Cancer gene therapy · 2012Article
- Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells.Asian journal of andrology · 2010Article
- Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Current issues and future directions of oncolytic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Adenoviral vector-based strategies for cancer therapy.Current drug therapy · 2009Article
- MicroRNAs and the regulation of vector tropism.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.Journal of virology · 2008Article
- Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.Journal of molecular medicine (Berlin, Germany) · 2008Review
- Characterization of an Oncolytic Adenovirus Vector Constructed to Target the cMet Receptor.Oncolytic virotherapyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundIn view of the limited success of available treatment modalities for a wide array of cancer, alternative and complementary therapeutic strategies need to be developed. Virotherapy employing conditionally replicative adenoviruses (CRAds) represents a promising targeted intervention relevant to a wide array of neoplastic diseases. Critical to the realization of an acceptable therapeutic index using virotherapy in clinical trials is the achievement of oncolytic replication in tumor cells, while avoiding non-specific replication in normal tissues. In this report, we exploited cancer-specific control of mRNA translation initiation in order to achieve enhanced replicative specificity of CRAd virotherapy agents. Heretofore, the achievement of replicative specificity of CRAd agents has been accomplished either by viral genome deletions or incorporation of tumor selective promoters. In contrast, control of mRNA translation has not been exploited for the design of tumor specific replicating viruses to date. We show herein, the utility of a novel approach that combines both transcriptional and translational regulation strategies for the key goal of replicative specificity.
methodsWe describe the construction of a CRAd with cancer specific gene transcriptional control using the CXCR4 gene promoter (TSP) and cancer specific mRNA translational control using a 5'-untranslated region (5'-UTR) element from the FGF-2 (Fibroblast Growth Factor-2) mRNA.
resultsBoth in vitro and in vivo studies demonstrated that our CRAd agent retains anti-tumor potency. Importantly, assessment of replicative specificity using stringent tumor and non-tumor tissue slice systems demonstrated significant improvement in tumor selectivity.
conclusionsOur study addresses a conceptually new paradigm: dual targeting of transgene expression to cancer cells using both transcriptional and mRNA translational control. Our novel approach addresses the key issue of replicative specificity and can potentially be generalized to a wide array of tumor types, whereby tumor selective patterns of gene expression and mRNA translational control can be exploited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.